Venture Capital

Navigator Medicines pushes two novel bispecific antibodies for Hidradenitis Suppurativa, promising better efficacy and patient-friendly dosing.

A federal court sided with Vitti Labs, ruling the FDA's interpretation of tissue rules "plainly erroneous." The decision could reshape the entire industry.

Independent firm FPA is nominated for a top Morningstar award alongside PIMCO and Vanguard, highlighting its rare focus on investor returns over asset size.

Despite citizenship law debates, investor demand for Portugal's Golden Visa remains strong, signaling a strategic shift towards long-term residency.

As co-founder Jürgen Bickel steps down, 14-year veteran David Männer takes the helm to navigate Storz & Bickel's future and drive Canopy's U.S. plans.

With a $150M war chest, OnKure pivots to a new class of PI3Kα inhibitors, aiming to revolutionize treatment for breast cancer and rare diseases.

With a fresh Nasdaq listing and $57.2M in funding, Satellos is advancing a novel muscle-regenerating drug for Duchenne into pivotal pediatric trials.

Kontrol Technologies targets Ontario's aging apartments with a strategic HVAC buyout, but its cautious M&A history reveals a complex path forward.

The company aims to slash production costs by 50% with AI, while deploying a powerful open-source agent that brings both promise and significant risk.

Biocon names 30-year veteran Shreehas Tambe as its new CEO, consolidating its biosimilar and generics arms to create a global biopharma powerhouse.

The pharma giant's acquisition of Excellergy and its first-in-class Exl-111 could revolutionize treatment for millions with severe, debilitating allergies.

Agenus prepares a crucial update on its BOT+BAL immunotherapy, a potential breakthrough for cancers resistant to current treatments. What will they reveal?

OPAL Fuels' Co-CEO will keynote at ACT Expo, highlighting how renewable natural gas offers fleets a path to cost savings and deep decarbonization.

At a key investor conference, Renibus is pitching its two Phase 3 drugs, including one with a strategic pivot after a challenging trial result.

With $12M in new funding, a Houston startup is deploying its NASA-derived HVAC retrofit that promises to slash building energy bills by over 50%.

A new report slams the FDA for blocking vital treatments with rising costs and denials, but the agency faces a complex reality of reform and internal pressure.

A new report reveals a stark divide in U.S. child care funding. A family's access to care—and their economic future—increasingly depends on their state.

An Austin-based firm's rapid expansion to 150 partners shows how CE/CME is moving from conference halls to podcasts, apps, and on-demand platforms.

The World Series of Poker is back on ESPN with a new format and producer Peyton Manning. Can this high-stakes partnership recapture the magic of the 2000s?

Cult popcorn brand Opopop is betting its bold flavors can disrupt the snack aisle with a nationwide Walmart launch. Can this online darling win over the masses?